Market Cap 551.45M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 1,089,660
Avg Vol 1,476,588
Day's Range N/A - N/A
Shares Out 78.44M
Stochastic %K 11%
Beta 0.72
Analysts Strong Sell
Price Target $12.57

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
Main_Street_Risks
Main_Street_Risks Feb. 3 at 12:54 AM
$REPL 1 these thing has a chart from another planet. The 1 yr chart is something. Gaps all over the place. And we know we aren’t done. So as we approach Pdufa where do we go? Pricing in higher liklihood of approvals with an SP up over $10 or so we price in another CRL down by $4. Perhaps we chop here in the middle
1 · Reply
JFais
JFais Jan. 28 at 1:36 PM
$RGNX- gap down to $8.70, price alerts triggered & back on my DD list for some point Pivotal DMD data in early Q2 (perhaps better safety & benefit vs $SRPT Elevidys given inclusion of C-Terminal domain, to capture younger patient population) Topline wet AMD data in Q4 (first GTx to make it to finish line) Con side= farther down my queue due to regulatory risk (unpredictable FDA including on acceptance of biomarker endpoints, could do a 180 as with $QURE, $ATRA, $REPL, etc)
1 · Reply
SeeingGreen420
SeeingGreen420 Jan. 25 at 1:35 AM
$ALT $ARVN $REPL 100% bioDICK is a paid basher and the CEO of Stocktwits lets it happen and has his back. He has many accounts and is 100% engagement farming for Stocktwits which makes their numbers look good for future IPO reasons I would imagine or straight private gains as well. The ALT board had the pleasure of this CEO popping in and disrespect us, back BioRich, and talk trash about ALT. Absolute garbage behavior from a CEO of a platform like this. Calculated manipulation involving Stocktwits, Kersdale CRAPital, law firms being paid by the hedge funds to spoof lawsuits and create bearish headlines with a court filing that never has merit, and price suppressing likely by the ones bidding for our company for the better part of 2 years is a sign of the rich hoarding an asset that’s yet to materialize!! We just received breakthrough therapy designation for Pemvi in MASH, that means = See MDGL valuation = our drug is better with weight loss = welcome to the future ladies and gents!!
2 · Reply
TraderJoe65
TraderJoe65 Jan. 25 at 12:29 AM
$ALT I agree. If I remember him correctly he was trying to shake everyone off $ARVN when it was 6 after study results and then $REPL after it fell to 3 . I wouldn't be surprised he is suppressing prices for an unethical hedge fund accumulating.
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 23 at 8:48 PM
$REPL Current Stock Price: $7.72 Contracts to trade: $10 REPL Jan 23 2026 Call Entry: $0.40 Exit: $0.51 ROI: 28% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
VolterX
VolterX Jan. 23 at 1:04 PM
$REPL biotech small cap coil with squeeze risk if catalysts appear
0 · Reply
bobby1234567891011
bobby1234567891011 Jan. 22 at 7:13 PM
$REPL banging right intonthe 200 MA
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 22 at 4:18 PM
$REPL Share Price: $7.73 Contract Selected: Feb 13, 2026 $10 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.63 – $0.76 Potential Upside: 55% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AllinGambler
AllinGambler Jan. 21 at 2:26 PM
$REPL suspicious whats happening with the volume, buy out in the works perhaps?
2 · Reply
bobby1234567891011
bobby1234567891011 Jan. 21 at 1:58 PM
$REPL 1.93 million dollar buy at 820
0 · Reply
Latest News on REPL
Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 4 months ago

Replimune Provides Update Following Type A Meeting with FDA


Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 5 months ago

Replimune Announces Type A Meeting Scheduled with FDA


Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 6 months ago

Replimune Group: The Prospects For FDA Approval After Rejection


Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 6 months ago

Why Is Replimune Stock Trading Lower On Monday?


Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 9 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript


Main_Street_Risks
Main_Street_Risks Feb. 3 at 12:54 AM
$REPL 1 these thing has a chart from another planet. The 1 yr chart is something. Gaps all over the place. And we know we aren’t done. So as we approach Pdufa where do we go? Pricing in higher liklihood of approvals with an SP up over $10 or so we price in another CRL down by $4. Perhaps we chop here in the middle
1 · Reply
JFais
JFais Jan. 28 at 1:36 PM
$RGNX- gap down to $8.70, price alerts triggered & back on my DD list for some point Pivotal DMD data in early Q2 (perhaps better safety & benefit vs $SRPT Elevidys given inclusion of C-Terminal domain, to capture younger patient population) Topline wet AMD data in Q4 (first GTx to make it to finish line) Con side= farther down my queue due to regulatory risk (unpredictable FDA including on acceptance of biomarker endpoints, could do a 180 as with $QURE, $ATRA, $REPL, etc)
1 · Reply
SeeingGreen420
SeeingGreen420 Jan. 25 at 1:35 AM
$ALT $ARVN $REPL 100% bioDICK is a paid basher and the CEO of Stocktwits lets it happen and has his back. He has many accounts and is 100% engagement farming for Stocktwits which makes their numbers look good for future IPO reasons I would imagine or straight private gains as well. The ALT board had the pleasure of this CEO popping in and disrespect us, back BioRich, and talk trash about ALT. Absolute garbage behavior from a CEO of a platform like this. Calculated manipulation involving Stocktwits, Kersdale CRAPital, law firms being paid by the hedge funds to spoof lawsuits and create bearish headlines with a court filing that never has merit, and price suppressing likely by the ones bidding for our company for the better part of 2 years is a sign of the rich hoarding an asset that’s yet to materialize!! We just received breakthrough therapy designation for Pemvi in MASH, that means = See MDGL valuation = our drug is better with weight loss = welcome to the future ladies and gents!!
2 · Reply
TraderJoe65
TraderJoe65 Jan. 25 at 12:29 AM
$ALT I agree. If I remember him correctly he was trying to shake everyone off $ARVN when it was 6 after study results and then $REPL after it fell to 3 . I wouldn't be surprised he is suppressing prices for an unethical hedge fund accumulating.
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 23 at 8:48 PM
$REPL Current Stock Price: $7.72 Contracts to trade: $10 REPL Jan 23 2026 Call Entry: $0.40 Exit: $0.51 ROI: 28% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
VolterX
VolterX Jan. 23 at 1:04 PM
$REPL biotech small cap coil with squeeze risk if catalysts appear
0 · Reply
bobby1234567891011
bobby1234567891011 Jan. 22 at 7:13 PM
$REPL banging right intonthe 200 MA
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 22 at 4:18 PM
$REPL Share Price: $7.73 Contract Selected: Feb 13, 2026 $10 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.63 – $0.76 Potential Upside: 55% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AllinGambler
AllinGambler Jan. 21 at 2:26 PM
$REPL suspicious whats happening with the volume, buy out in the works perhaps?
2 · Reply
bobby1234567891011
bobby1234567891011 Jan. 21 at 1:58 PM
$REPL 1.93 million dollar buy at 820
0 · Reply
HeyHeyBooBoo
HeyHeyBooBoo Jan. 20 at 4:34 PM
$REPL All Aboard!
0 · Reply
Warren_Buffet3
Warren_Buffet3 Jan. 20 at 9:03 AM
$REPL Can this go under 1 $ in April after the CRL? I would want to load up for that price... Now it's crazy expensive!
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 16 at 6:33 PM
0 · Reply
jrw06
jrw06 Jan. 16 at 10:53 AM
$REPL Looks like there could be a trend reversal for those swing traders out there. Interestingly also appears their CEO + bunch of execs significantly increased their stock holdings last month (source Bio Pharma Catalyst). Watching today and may start a small position
1 · Reply
Dorps332
Dorps332 Jan. 15 at 5:28 PM
$REPL I take it what ever they said at the JPM conference didn’t go well with investors
1 · Reply
Doplrshift
Doplrshift Jan. 15 at 3:18 PM
$REPL this part says it all: “500 Unicorn Park Drive Suite 303 Woburn , MA 01801”
0 · Reply
JFais
JFais Jan. 14 at 11:51 PM
$REPL- another victim of FDA unpredictability ($10 to $7S, bio rundown into July PDUFA vs the usual run-up)
0 · Reply
Evagaminska
Evagaminska Jan. 12 at 3:00 PM
$ATRA IMHO even though it doesn’t matter much think these companies should form some task force to expose this clown show at FDA Let’s do $REPL company does what is asked of them but still gets magically CRL then two months later Big Pharma gets approval for melanoma cancer EU is much stricter with their approval considering different countries form the union yet treatment gets approved but Prasad gives NDA&CRL to USA small biotech like freaking candies Why did Trump cave and let FDA rehire him? 47 nickname should be caver king
0 · Reply
TopCharts
TopCharts Jan. 12 at 2:25 PM
$ATRA Second CRL wow following steps for $OTLK $CORT $REPL is seems to be next in fda CRL fire
0 · Reply
Stmkr
Stmkr Jan. 12 at 1:44 PM
$ATRA $QURE $REPL $CAPR I think ATRA wins as the most ridiculous CRL by this FDA so far.
1 · Reply
tpurt725
tpurt725 Jan. 12 at 3:33 AM
$REPL JPM healthcare conference this week. Replimune presenting Wednesday. Fingers crossed good news is shared and potential buyers are impressed.
0 · Reply
Warren_Buffet3
Warren_Buffet3 Jan. 9 at 6:42 PM
$REPL Seems like market strongly expect another CRL on April. Then price could drop back to 2 $. What are your opinions?
4 · Reply